Vendor Intelligence Report: DAHAN Peptide

Published 3 Jul 2026. 20-page investigative report on who is behind DAHAN Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, DAHAN Peptide records 4 pass / 0 fail for an overall pass rate of 80%. The favorable part is narrow: the Finnrick file is essentially a Tirzepatide read, with positive DAHAN results concentrated in the only tested product and no basis to extend that confidence across the advertised catalog.

The corporate file is much less tidy. DAHAN uses manufacturer-style language, but the dated records point to a recent web presence, a DAHAN-named Hong Kong entity lead that is no longer active, and an ICP footer that points to the official portal without displaying a filing number.

The web-infrastructure trail is the investigation’s main hook. DAHAN sits inside a cloned peptide-storefront cluster on one Alibaba Cloud host, and a sister About page accidentally carries DAHAN wording inside another brand’s copy. A separate contact-page pivot places a DAHAN sales email in the Y.H Peptide / TopXPeptides orbit; the report separates that operational link from proof of legal ownership.

The product-specific read is directional rather than blanket. DAHAN is comparatively more defensible for Tirzepatide than for Retatrutide, BPC-157, HGH, or other DAHAN items not covered in the supplied Finnrick data; methodology-sensitivity charts stress that single-product record rather than proving catalog-wide quality. The report also explains the missing public DAHAN Janoshik trail and the payment-verification implications of consumer email channels and weak email authentication.

Inside the full report:

  • Per-product pass/fail detail, rating trajectory, and methodology-divergence charts for the single DAHAN-tested product
  • Dated evidence timeline covering domain registration, the Hong Kong entity lead, dissolution, and Finnrick testing milestones
  • Reverse-IP and infrastructure analysis of the cloned DAHAN, LEDA, SM Peptide, and YB Peptide storefront cluster
  • Corporate-identity review with Hong Kong identifiers, ICP/Beian lookup results, and mainland entity-search dead ends
  • Contact-page and email-pivot exhibits linking DAHAN sales identities with the Y.H Peptide / TopXPeptides lead
  • Exhibit gallery including homepage captures, the LEDA copy-paste error, contact roster, products snapshot, and Janoshik zero-results capture

Risk assessment

  • Multi-storefront brand-confusion and network-opacity risk — high: DAHAN, LEDA, SM Peptide, and YB Peptide share one Alibaba Cloud IP and cloned storefront language; LEDA's About page accidentally names DAHAN, and DAHAN provides no authoritative channel or reseller list.
  • Corporate-accountability and regulatory-status risk — high: The only identified DAHAN-named Hong Kong entity lead was dissolved on November 28, 2025; no replacement entity, mainland manufacturer record, or ICP filing was identified for dhpeptide.com.
  • Misleading operating-history and facility-claim risk — high: The cluster repeats “over 20 years” and “3 GMP standard workshop” claims, but the dated records show 2025 domains, a 2023 Hong Kong entity lead now dissolved, and no verified current manufacturer.
  • Untested broader-catalog quality and batch-verification risk — medium: Finnrick coverage is favorable for Tirzepatide only (4 tests, 4 pass, 0 fail, 82.79%); Semaglutide, Retatrutide, BPC-157, TB-500, HGH, and other DAHAN catalog products lack supplied Finnrick coverage, and Janoshik shows zero DAHAN results.